Passa al contenuto
Merck

R3530

Rifabutin

>98% (HPLC), powder, antibiotic

Sinonimo/i:

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

5 MG

CHF 178.00

25 MG

CHF 694.00

CHF 178.00


Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C46H62N4O11
Numero CAS:
Peso molecolare:
847.00
UNSPSC Code:
12352200
NACRES:
NA.77

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

Rifabutin, >98% (HPLC), powder

SMILES string

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

InChI key

ATEBXHFBFRCZMA-VXTBVIBXSA-N

assay

>98% (HPLC)

form

powder

storage condition

protect from light

solubility

DMSO: >5 mg/mL

antibiotic activity spectrum

neoplastics

mode of action

enzyme | inhibits

originator

Johnson & Johnson

shipped in

wet ice

storage temp.

−20°C

Quality Level

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
1603800Y0000149PHR2611
Rifabutin >98% (HPLC), powder

Sigma-Aldrich

R3530

Rifabutin

USP

USP

1603800

Rifabutin

vibrant-m

Y0000149

Rifabutin

Rifabutin Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2611

Rifabutin

form

powder

form

-

form

-

form

solid

assay

>98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

300

storage temp.

−20°C

storage temp.

-

storage temp.

2-8°C

storage temp.

-10 to -25°C

storage condition

protect from light

storage condition

-

storage condition

-

storage condition

-

solubility

DMSO: >5 mg/mL

solubility

-

solubility

-

solubility

-

Biochem/physiol Actions

Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.
Rifabutin is an antibiotic; antitumor.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

C Y Tay et al.
Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)
Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the
Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug
Matthew D Hickey et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)
Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from
Kelly E Dooley et al.
Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)
Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF
J P Gisbert et al.
Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)
In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had

Articoli

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica